VisionGate, Inc.

VisionGate, Inc. is a biotechnology company focused on developing advanced lung cancer detection technologies through non-invasive methods, significantly enhancing early diagnosis and treatment outcomes. Founded in 2001 and headquartered in Phoenix, US, VisionGate, Inc. specializes in innovative lung cancer detection solutions.

The company has participated in 7 deals, with its most recent deal occurring on June 6, 2019, raising USD 3. 75 mn in funding. VisionGate has not undergone any significant business pivots or structural changes since its inception. VisionGate specializes in innovative lung cancer detection technologies aimed at high-risk patients through non-intrusive testing methods.

The company's flagship product, the LuCED° Lung Test, utilizes sputum samples collected over three days via a take-home kit to analyze for early signs of lung cancer. High-resolution 3D cellular imaging is employed to generate detailed images of the sputum cells, which are then assessed using AI-powered classifiers designed to identify abnormal cellular structures. This breakthrough technology is pivotal in enhancing early detection, thereby improving treatment outcomes when the chance for a cure is maximized. VisionGate has established partnerships with leading healthcare institutions in various regions, including but not limited to the United States and the Netherlands, serving a diverse clientele that includes healthcare providers and research institutions focused on cancer prevention and detection.

VisionGate's revenue model is primarily structured around partnerships and collaborations with healthcare institutions and academic organizations, facilitating the distribution of their proprietary lung cancer detection services. The company engages in B2B transactions wherein healthcare providers utilize the LuCED° Lung Test as part of their diagnostic offerings. Revenue is generated through service agreements and testing fees associated with the use of their patented 3D imaging technology and AI analysis. These agreements typically cover the costs of the take-home testing kits and subsequent analysis, allowing clients to offer advanced diagnostic services to their patients.

By aligning with major healthcare systems, VisionGate enhances its market reach and ensures a steady inflow of revenue through its innovative cancer detection solutions. VisionGate is actively designing new products to expand its lung cancer detection capabilities. The company aims to launch additional diagnostic tools by the end of 2023, enhancing its product line. Following its recent funding round where USD 3.

748 mn was raised in June 2019, VisionGate plans to utilize these resources to support its product development and facilitate entry into new geographic markets, including Europe and Asia, by 2024. This expansion is intended to broaden access to its lung cancer detection technologies to a wider patient population.